Objective To explore the curative efficacy of Entecavir in the treatment of patients with chronic severe hepatitis B. Methods 50 patients with chronic severe hepatitis B from June 2010 to September 2011 in our hospital were divided into observation group and control group, with 25 cases in each group. Medical comprehensive treatment was used in the two groups, and also Entecavir was used in the observation group, 0.5 mg po, 1 time/d. Liver function enzymes, time of blood enzymes and HBVDNA level were recorded, and the efficacy was observed in the two groups. Results There was no difference on the liver function enzymes, the time of blood enzymes and HBV DNA level of the two groups before treatment (P > 0.05), the liver function enzymes, time of blood enzymes after treatment of 4, 8, 12 weeks, and HBV DNA level after treatment of 4, 8 weeks, there were significant differences in the two groups (P < 0.05, P < 0.01). After treatment of 12 weeks, HBV DNA level was decreased under the 103 copies/mL, there was a significant difference about the percentage (100%, 24%) in the observation group and control group (P < 0.05). No adverse reaction about the entecavir in the treatment, and good tolerance. Conclusion The curative efficacy of Entecavir is effective and safe in the treatment of patients with chronic severe hepatitis B, can significantly improve the patient's condition and improve survival rate. It is worthy of promotion and application.%目的 探讨恩替卡韦治疗慢性重型乙型肝炎早期患者的疗效.方法 选取2010年6月～2011年9月我院收集的慢性重型乙型肝炎患者50例,将其随机分为治疗组和对照组,各25例.对照组给予内科综合治疗,治疗组在此基础上给予口服恩替卡韦0.5 mg治疗,1次/d.记录两组治疗前及治疗后4、8、12周的肝功能酶、凝血酶原时间及血清HBV DNA水平,并观察两组的疗效.结果治疗组和对照组治疗前肝功能、凝血酶原时间,HBV DNA水平比较,差异均无统计学意义(P ＞ 0.05),治疗后4、8、12周肝功能、凝血酶原时间及治疗后4、8周HBV DNA水平比较,差异均有统计学意义(P ＜ 0.05、P ＜ 0.01).治疗后12周两组HBV DNA载量水平均低于检测值(103拷贝/mL),其所占比例(100%、24%)比较,差异有统计学意义(P ＜ 0.05).治疗后12周,治疗组病情好转率[96%(24/25)]高于对照组[60%(15/25)](P ＜ 0.05).治疗过程中患者并未出现与恩卡替韦相关的不良反应,且耐受性较好.结论 恩替卡韦治疗慢性重型乙型肝炎早期效果好且比较安全,可显著改善患者的病情,提高生存率,值得推广应用.
展开▼
